Premium
The circadian rest‐activity rhythm, a potential safety pharmacology endpoint of cancer chemotherapy
Author(s) -
OrtizTudela Elisabet,
Iurisci Ida,
Beau Jacques,
Karaboue Abdoulaye,
Moreau Thierry,
Rol Maria Angeles,
Madrid Juan Antonio,
Lévi Francis,
Innominato Pasquale F.
Publication year - 2013
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.28587
Subject(s) - chronotherapy (sleep phase) , circadian rhythm , medicine , tolerability , chemotherapy , chronobiology , anesthesia , oncology , adverse effect
The robustness of the circadian timing system (CTS) was correlated to quality of life and predicted for improved survival in cancer patients. However, chemotherapy disrupted the CTS according to dose and circadian timing in mice. A continuous and repeated measures longitudinal design was implemented here to characterize CTS dynamics in patients receiving a fixed circadian‐based chemotherapy protocol. The rest‐activity rhythm of 49 patients with advanced cancer was monitored using a wrist actigraph for 13 days split into four consecutive spans of 3–4 days each, i.e ., before, during, right after and late after a fixed chronotherapy course. The relative amount of activity in bed vs . out of bed (I